Skip to Content

Cabozantinib

In the US, Cabozantinib (cabozantinib systemic) is a member of the following drug classes: multikinase inhibitors, VEGF/VEGFR inhibitors and is used to treat Renal Cell Carcinoma and Thyroid Cancer.

US matches:

Scheme

Rec.INN

CAS registry number (Chemical Abstracts Service)

0849217-68-1

Chemical Formula

C28-H24-F-N3-O5

Molecular Weight

501

Therapeutic Category

Antineoplastic agent: Tyrosine kinase inhibitor

Chemical Name

N-{4-[(6,7-dimetoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (WHO)

Foreign Names

  • Cabozantinibum (Latin)
  • Cabozantinib (German)
  • Cabozantinib (French)
  • Cabozantinib (Spanish)

Generic Names

  • Cabozantinib (OS: USAN)
  • BMS-907351 (IS)
  • UNII-1C39JW444G (IS)
  • XL-184 (IS)
  • Cabozantinib s-Malate (OS: USAN)
  • UNII-DR7ST46X58 (IS)

Brand Names

  • Cometriq
    TMC Pharma, Poland; TMC Pharma, Slovenia; Exelixis, United States; SOBI, Sweden; Swedish Orphan, Germany; Swedish Orphan Biovitrum, Finland; Swedish Orphan Biovitrum, United Kingdom

International Drug Name Search

Glossary

TermDefinition
ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Hide